{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.41","upperLimit":"2.10","value":"1.45"},{"groupId":"OG001","lowerLimit":"1.45","upperLimit":"2.79","value":"1.84"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"201"},{"groupId":"OG001","value":"197"}],"units":"Participants"}],"title":"Global Health Status/QoL"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.99","upperLimit":"1.48","value":"1.41"},{"groupId":"OG001","lowerLimit":"0.95","upperLimit":"2.00","value":"1.41"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"202"},{"groupId":"OG001","value":"190"}],"units":"Participants"}],"title":"Role Functional Scale"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.45","upperLimit":"2.14","value":"1.81"},{"groupId":"OG001","lowerLimit":"2.07","upperLimit":"3.48","value":"2.79"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"209"}],"units":"Participants"}],"title":"Physical Functional Scale"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.50","upperLimit":"4.37","value":"3.48"},{"groupId":"OG001","lowerLimit":"2.14","upperLimit":"4.34","value":"2.83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"168"},{"groupId":"OG001","value":"171"}],"units":"Participants"}],"title":"Emotional Functional Scale"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.41","upperLimit":"2.14","value":"1.64"},{"groupId":"OG001","lowerLimit":"1.41","upperLimit":"2.07","value":"1.45"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"167"}],"units":"Participants"}],"title":"Cognitive Functional Scale"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.38","upperLimit":"1.64","value":"1.45"},{"groupId":"OG001","lowerLimit":"1.35","upperLimit":"1.45","value":"1.41"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"189"},{"groupId":"OG001","value":"171"}],"units":"Participants"}],"title":"Social Functional Scale"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.76","upperLimit":"1.25","value":"0.92"},{"groupId":"OG001","lowerLimit":"0.76","upperLimit":"1.38","value":"0.89"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"210"},{"groupId":"OG001","value":"204"}],"units":"Participants"}],"title":"Fatigue Symptom Scale"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.41","upperLimit":"1.64","value":"1.45"},{"groupId":"OG001","lowerLimit":"0.95","upperLimit":"1.45","value":"1.41"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"173"}],"units":"Participants"}],"title":"Nausea and Vomiting Symptom Scale"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.41","upperLimit":"2.10","value":"1.64"},{"groupId":"OG001","lowerLimit":"1.45","upperLimit":"2.76","value":"2.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"183"}],"units":"Participants"}],"title":"Pain Symptom Scale"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.45","upperLimit":"2.76","value":"2.10"},{"groupId":"OG001","lowerLimit":"1.45","upperLimit":"2.79","value":"2.07"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"160"}],"units":"Participants"}],"title":"Dyspnea Symptom Scale"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.45","upperLimit":"2.79","value":"2.10"},{"groupId":"OG001","lowerLimit":"1.41","upperLimit":"2.33","value":"1.58"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"160"}],"units":"Participants"}],"title":"Insomnia Symptom Scale"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.45","upperLimit":"2.04","value":"1.48"},{"groupId":"OG001","lowerLimit":"1.41","upperLimit":"2.14","value":"1.64"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"170"}],"units":"Participants"}],"title":"Appetite Loss Symptom Scale"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.41","upperLimit":"2.14","value":"1.48"},{"groupId":"OG001","lowerLimit":"1.41","upperLimit":"2.10","value":"1.45"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"105"}],"units":"Participants"}],"title":"Financial Difficulties Scale"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.41","upperLimit":"2.10","value":"1.64"},{"groupId":"OG001","lowerLimit":"1.41","upperLimit":"2.10","value":"1.41"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"157"}],"units":"Participants"}],"title":"Constipation Symptom Scale"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.45","upperLimit":"2.79","value":"2.07"},{"groupId":"OG001","lowerLimit":"2.10","upperLimit":"3.52","value":"2.79"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"148"}],"units":"Participants"}],"title":"Diarrhea Symptom Scale"}],"denoms":[{"counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"251"}],"units":"Participants"}],"description":"Time to first worsening was calculated as the time from the first study drug dose to the first observation of worsening according to the EORTC QLQ-C30 Scoring Manual (Fayers et al. 2001). The EORTC QLQ-C30 self-reported general cancer instrument consists of 30 total items covered by 1 of 3 dimensions (1 global health status/QoL total score, 5 functional subscales \\[physical, role, cognitive, emotional, and social\\]), and 9 symptom subscales \\[fatigue/nausea/vomiting/pain/dyspnea/insomnia/appetite loss/constipation/diarrhea\\]). There are 28 questions answered on a 4-point scale where 1=Not at all (best) to 4=Very Much (worst) and 2 questions answered on a 7-point scale where 1=Very poor (worst) to 7= Excellent (best). A linear transformation was used to obtain total score ranging from 0 to 100 where \"worsening\" was defined as an increase of at least 10 points for the symptom scales or a decrease of at least 10 points for the functional scales and the global health status/QoL scale.","dispersionType":"95% Confidence Interval","groups":[{"description":"75 milligrams per meter squared (mg/m\\^2) doxorubicin administered intravenously (IV) on day 1 of each 21 day cycle for 8 cycles plus 20 milligrams per kilogram (mg/kg) dose of olaratumab administered IV on day 1 and day 8 of cycle 1 and 15 mg/kg olaratumab administered IV on day 1 and day 8 of cycles 2-8. Beginning with cycle 9, 15 mg/kg olaratumab administered IV on day 1 and day 8 of each subsequent 21 day cycle until documented progressive disease (PD) or discontinuation for any other reason.","id":"OG000","title":"Doxorubicin + Olaratumab"},{"description":"75 mg/m\\^2 doxorubicin administered IV on day 1 of each 21 day cycle for 8 cycles plus placebo (equivalent volume) administered IV on day 1 and day 8 for 8 cycles. Beginning with cycle 9, placebo (equivalent volume) administered on days 1 and 8 of each subsequent 21 day cycle until PD or discontinuation for any other reason.","id":"OG001","title":"Doxorubicin + Placebo"}],"paramType":"MEDIAN","populationDescription":"All randomized participants who completed at least 1 baseline assessment and at least 1 subsequent assessment during the study period.","reportingStatus":"POSTED","timeFrame":"Randomization (Cycle 1) through Follow-up (Up to 35.8 Months)","title":"Time to First Worsening on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Scores","type":"SECONDARY","unitOfMeasure":"Months"}